Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Sprints Ahead Of India In Innovation Efforts, Says McKinsey Executive: Will The Gap Get Wider?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - China has far outpaced India on the innovation front even though the two Asian giants were at almost the same level barely 10 years ago, with China's rush ahead due to strong government initiatives on healthcare reforms and a constant flow of professionals with experience at Western global pharmaceutical companies returning to the motherland

You may also be interested in...



Rising Scientific Powers India And China Compete For Bigger Shares Of Expanding Market In R&D Outsourcing

BEIJING - Global pharmaceutical players are likely to step up the transfer of research to specialist firms across China and India over the next decade, as the Asian giants continue to evolve into major scientific powers

Rising Scientific Powers India And China Compete For Bigger Shares Of Expanding Market In R&D Outsourcing

BEIJING - Global pharmaceutical players are likely to step up the transfer of research to specialist firms across China and India over the next decade, as the Asian giants continue to evolve into major scientific powers

India’s Jubilant, Eli Lilly In Joint Venture To Develop Molecules

Jubilant Organosys of India and Eli Lilly created a joint venture to develop molecules to develop a variety of treatments, including cancer and diabetes. The evenly divided research and development venture intends to develop molecules through the Phase II stage as well as develop molecules for other pharmaceutical companies. The new company is to be based in India and begin operating before the end of the year, with the parent companies investing a combined $8 million over the next three years. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel